Therapeutics case studies

Learn more on how we bring life changing therapies to market.

Providing empirically based guidance and built-to-spec models and solutions across every phase of clinical research and lifecycle management for therapeutic development.

Imaging process boosts efficiency in oncology device trial

A prominent medical device company was conducting a feasibility study for a device to improve accurate identification of peripheral pulmonary nodules in high risk adult patients. Quality imaging data from multiple sources was critical to the study’s success and ICON helped manage the imaging data for each participant.

Leveraging Real-World Data and machine learning

Early cancer detection is vital, yet many cases—especially lung cancer—are diagnosed late, limiting treatment options. Life sciences organizations now use real-world data and machine learning to identify subtle, pre-diagnostic signals in patient journeys, enabling earlier intervention and improved outcomes.

doctor measuring blood pressure on patient

Line of therapy analysis to support commercialisation efforts of rare disease

Pulmonary arterial hypertension (PAH) often presents with vague symptoms, making diagnosis difficult and leading to frequent delays or misdiagnoses. While current treatments have improved outcomes, underserved populations with limited access to specialized care remain under treated.

Exceeding late phase study recruitment goals

Over 19 days, ICON conducted a focused site engagement programme to increase patient screening and accelerate enrolment of a late phase multinational, multicentre study to evaluate a treatment for pulmonary disease.

Hepatologists discussing liver treatments

Re-adjudicating a respiratory and cardiovascular trial during COVID-19

The FDA advised the trial to re-adjudicate so that the study accounted for the effects of COVID-19 on the trial outcomes. To ensure that the trial data would be submitted to the FDA as scheduled, ICON needed to coordinate re-adjudication of 700 endpoints within a compressed three-month timeline.

Doctor consultation with study participant

Allergic rhinitis

A Biotech client contracted ICON to conduct a Phase III study that was a double-blinded, randomised, multinational, multicentre, placebo-controlled trial.

Severe COPD phase III case study

A sponsor conducting an international Phase III program of two double-blind, randomised studies consulted ICON’s respiratory experts for assistance in patient enrolment, and study planning and monitoring.

Regulatory project management scenario planning (Oncology)

ICON was asked to provide scenario planning related to accelerating the marketing authorisation application (MAA) approval through various clock-stop scenarios.

Leveraging Immuno-Oncology real world data

ICON supported a randomised phase 3 study to examine the study drug in combination with nivolumab vs chemotherapy in patients with checkpoint inhibitor refractory non-squamous NSCLC.

Successful adaptation to complex dose escalation

ICON was selected by a mid-size biotech company to support a phase 1 dose escalation and cohort expansion study of an immune checkpoint inhibitor, in patients with advanced solid tumors. Mid-study, the sponsor was acquired by a large pharma company to which ICON has efficiently supported the transition to the evolving sponsor business model and operations.

Overcoming challenges in non small cell lung carcinoma rescue study

A mid sized Pharma organisation was conducting a Phase Ib trial with plans to enroll 188 Non Small Cell Lung Carcinoma patients in Cohort B.

Cardiac imaging and monitoring support for PAH trial

ICON provided a large pharma sponsor with consistent, accurate ECG and ECHO modality imaging, contributing to a breakthrough pulmonary arterial hypertension treatment.